2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

4:30PM-6:00PM: Abstract Number: 899

Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout

3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

4:30PM-6:00PM: Abstract Number: 891

Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 950

Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

4:30PM-6:00PM: Abstract Number: 886

Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 926

Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 888

Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 928

Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks

3S109: RA – Treatments II: Novel Treatments for RA (927–932)

4:30PM-6:00PM: Abstract Number: 897

Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 918

Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 907

Musculoskeletal Sarcoidosis: Characterization and Clinical Expression of 129 Patients with Granulomatous Infiltration of Bones And/or Muscles

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: Abstract Number: 930

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator

3S109: RA – Treatments II: Novel Treatments for RA (927–932)

4:30PM-6:00PM: Abstract Number: 911

Perfusion in Bone Marrow Lesions Assessed on Dynamic Contrast-enhanced MRI and Its Association with Pain in Knee Osteoarthritis: A Cross-sectional Study

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: Abstract Number: 954

Physical Therapy and Opioid Use in Knee Osteoarthritis

3S089: Health Services Research I: Clinical Perspectives (951–956)

4:30PM-6:00PM: Abstract Number: 934

Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis

3S111: Spondyloarthritis Including Psoriatic Arthritis – Clinical II: Axial Spondyloarthritis Treatment (933–938)

4:30PM-6:00PM: Abstract Number: 903

Prevalence of Atopic Features in Classic Autoinflammatory Diseases

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].